Targets › FKBP12
1 program from 1 company in 2 trials: 1 Phase 3, 1 Phase 2; Infectious disease.
Keeps in an inactive conformation TGFBR1, the TGF-beta type I serine/threonine kinase receptor, preventing TGF-beta receptor activation in absence of ligand. Recruits SMAD7 to ACVR1B which prevents the association of SMAD2 and SMAD3 with the activin receptor complex, thereby blocking the activin signal. (UniProt, P62942)
Open in Phaseline: the race on FKBP12, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| F2G | Olorofim (F901318) Dihydroorotate dehydrogenase (quinone), mitochondrial inhibitor | FKBP12 | Phase 3 | Invasive Aspergillosis; Coccidioidal Meningitis | – |
Invasive Aspergillosis (1) Coccidioidal Meningitis (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.